Patient voices Eves story
Eve’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Search
Patient voices Ulrichs story
Ulrich’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Diabetes
Diabetes
BI Focuses COVID-19 Clinical Research on Alteplase
BI focuses its COVID-19 therapy research on the development of alteplase as a potential treatment for COVID-19 patients with severe breathing problems
About cardio-renal-metabolic conditions
This page provides an overview of cardiovascular, renal, and metabolic conditions
EMPRISE-interim-analysis
Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
MASH
MASH
Striving to revolutionize mental health research
World Mental Health Day: Through a precision psychiatry approach and rich pipeline, we are committed to transforming the mental health landscape.
Iclepertin: GlyT1 inhibitor
Iclepertin: GlyT1 inhibitor
cat dog flea allergy dermatitis
Find out how you can identify and treat flea allergy dermatitis, one of the most common illnesses associated with a flea infestation.
Pulmonary Fibrosis: Early discovery makes all the difference
Video taking a deep dive into pulmonary fibrosis. Visit an underwater world that brings to life the physical change PF has on the lungs.
CT-155: Prescription digital therapeutic
CT-155: Prescription digital therapeutic
BI increases commitments to sustainable development
At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development
Netherton Syndrome
Information on Netherton Syndrome, a severe, ultra-rare multisystem disorder which has a life-altering impact across a person’s life.
Boehringer Ingelheim strong growth pipeline acceleration 2023
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
GPP
GPP
The Unwearable Collection™: Fashion Inspired by GPP
An introduction to The Unwearable Collection™: fashion inspired by the experiences of living with GPP, designed by Bart Hess
1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
Leptospirosis dogs pet owner guide
The disease can affect multiple organs in dogs, causing kidney damage, liver failure, and even death. The most effective prevention method is vaccination.
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
empa-reg-outcome-recurrent-events
EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
Improving Access to Healthcare
According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
Partnering in Central Nervous System Diseases
We are looking for new early-science collaborations. Join our expanding community of innovation partners in central nervous system diseases.
About Chronic Kidney Disease
CKD is very common and often goes undetected due to its silent nature. Risk factors include high blood pressure and type 2 diabetes.
Bluetongue disease
The bluetongue virus is a viral disease that affects ruminants' health. It doesn't affect humans, but it is a threat to animals.